Group 1: Novo Nordisk and Competitive Landscape - Novo Nordisk's stock reached a 52-week low following the failure of its REDEFINE 4 trial to show non-inferiority in weight loss compared to Eli Lilly's tirzepatide, with weight loss results of 20.2% for CagriSema versus 23.6% for tirzepatide [1] - The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema showed a safe profile, the results did not meet market expectations [1] - The GLP-1/GIP dual agonist class is expected to maintain market leadership in the U.S. due to optimal efficacy and tolerability, despite the increasing number of new entrants [2] Group 2: Viking Therapeutics and VK2735 - Viking Therapeutics is advancing its oral formulation of VK2735, which is anticipated to enter Phase 3 trials in Q3 2026, offering both injectable and oral options [4] - The REDEFINE 4 results contribute to the evidence supporting the competitive positioning of VK2735 alongside other drugs in Phase 3 development [3] - Viking's stock has shown mixed technical signals, trading above its 20-day simple moving average but below its 50-day and 100-day SMAs, indicating potential challenges [5] Group 3: Stock Performance and Analyst Consensus - Viking Therapeutics shares were up 10.91% at $34.41, with an average price target of $92.44 and a Buy Rating from analysts [7] - Key resistance for Viking's stock is at $36.00, while key support is at $29.50 [7] - Recent analyst actions include Canaccord Genuity raising its target to $107.00 and JP Morgan lowering its target to $75.00 [7]

Core Viewpoint - Cantor Fitzgerald believes that Viking Therapeutics' GLP-1 diet drug VK2735 has the potential to become a "multi-blockbuster," significantly boosting the company's stock value [1][4]. Group 1: Stock Performance - Viking Therapeutics' shares increased by 12.5% on Tuesday following positive endorsements from Wall Street analysts [1]. - The stock saw a rise after Truist Securities analyst Joon Lee lowered his price target but predicted benefits from phase 3 clinical trial news for VK2735 [2]. Group 2: Analyst Predictions - Cantor Fitzgerald's analyst Steven Seedhouse predicts that Viking's stock price could quadruple from $29 to $104 within a year, emphasizing a strong buy recommendation [2]. - Seedhouse's thesis is centered on VK2735, which is entering phase 3 development for general obesity, and he believes that even the injectable form alone could more than triple the stock's value [3]. Group 3: Drug Comparison and Potential - Seedhouse argues that VK2735's formulation is superior to Eli Lilly's tirzepatide, suggesting it will outperform Lilly's Zepbound and Mounjaro [4]. - The potential development of a VK2735 pill, which would eliminate the need for injections, is seen as an additional positive factor, with phase 2 data expected in the second quarter of 2025 [3].